Clearside Biomedical Submits New Drug Application for XIPERE for the Treatment of Macular Edema Associated with Uveitis
pharmaceutical investing Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA
pharmaceutical investing Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
Equity Metals Reports Assays from 2026 Validation Drilling on the No. 3 Vein and Active Q4 Exploration Initiatives, Silver Queen Project, BC
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
SAGA Metals Drills 495.6 m at 37.86% Fe2O3, 5.51% TiO2, 0.273% V2O5 Including 68.2 m at 52.95% Fe2O3, 8.57% TiO2, 0.381% V2O5 at Radar Critical Minerals Project in Labrador
